

PRESCRIBE WITH CONFIDENCE

Clinically Proven Efficacy^{1,2}



The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) has conducted the 2019 LAMP-1 study and 2023 LAMP-2 Study, randomised placebo-controlled trials of low-dose atropine in children to prevent myopia progression as well as its onset respectively. All eye drops were prepared by Aseptic Innovative Medicine Co, LTD, Taipei, Taiwan, in mono-dose preparation.

Results shows that low-concentration atropine eye drops can significantly reduce myopia progression and prevent myopia in children.^{1,2}

Preservatives Free



Avoid secondary damage to human eye. European Medicines Agency stated that benzalkonium chloride (BAC) had been reported to cause⁵ :


1. Punctate keratopathy and/or toxic ulcerative keratopathy.
2. Eye irritation.
3. Discolouring of soft contact lenses.
4. Increasing conjunctival inflammation and potential effects on the cornea.
5. Worsening of abnormal tearing and/or ocular surface disease.

No Contamination



Adopt automated, streamlined blow-fill-seal manufacturing system, German production technology which decrease the risk of contamination:

1. Integrally formed container
2. No contact environment since container is formed immediately before the sterile product is filled
3. Small container openings and negligible product exposure times, further decreasing bacterial access



Watch Video



Quality Assurance



1. The world's first pharmaceutical certification certified⁶
2. Meet PIC/S GMP international production standard.
3. The plastic materials are approved by the U.S. and European Pharmacopoeia.
4. Used in published clinical trials.



TFDA Drug License



TFDA PIC/S GMP

ATROPINE EYE DROPS FOR MYOPIA MANAGEMENT

REDUCE MYOPIA PROGRESSION AND PREVENT MYOPIA IN CHILDREN^{1,2}



ATROPINE 0.025%
0.5ML UNIT DOSE

Clinically Proven¹⁻⁴

- Published **publicly** •
- Clinical trials with more than **1,000 participants**



ATROPINE 0.01%
0.5ML UNIT DOSE



ATROPINE 0.05%
0.5ML UNIT DOSE



ATROPINE 0.125%
0.5ML UNIT DOSE



PRESERVATIVES
FREE



NO
CONTAMINATION



QUALITY
ASSURANCE

Abbreviations: SL: ISpherical Equivalent; AL: Axial Length
References: 1. Yam, Jason C et al. "Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control." *Ophthalmology* vol. 126,1 (2019): 113-124. doi:10.1016/j.ophtha.2018.05.029 2. Yam, Jason C et al. "Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial." *JAMA* vol. 329,6 (2023): 472-481. doi:10.1001/jama.2022.24162 3. Cheng, Han-Chih, and Yi-Ting Hsieh. "The effect of low-concentration atropine combined with auricular acupoint stimulation in myopia control." *Complementary therapies in medicine* vol. 22,3 (2014): 449-55. doi:10.1016/j.ctim.2014.03.004 4. Clark, Tiana Y, and Robert A Clark. "Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia." *Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics* vol. 31,9 (2015): 541-5. doi:10.1089/jop.2015.0043 5. Committee for Human Medicinal Products (CHMP) Questions and Answers on Benzalkonium Chloride Used as an Excipient in Medicinal Products for Human Use. 2017. 6. The world's first pharmaceutical certification in Atropine eye drops certified by TFDA.

Images are for illustration purpose.
© Jacobson Medical (Hong Kong) Limited. All Rights Reserved.

DISTRIBUTOR
JACOBSON
MEDICAL
Jacobson Medical (Hong Kong) Ltd.
雅各臣藥業(香港)有限公司

TEL: (852) 2267 2298 FAX: (852) 2790 9300
E-MAIL: INFO@JACOBSONMEDICAL.COM.HK

MANUFACTURER
AIM 麥迪森

ASEPTIC INNOVATIVE MEDICINE CO., LTD.
WWW.AIMEDICINE.COM.TW



FOR HEALTHCARE PROFESSIONALS ONLY

Low-concentration atropine is an effective and safe intervention for children aged 4 – 12 years old to reduce myopia progression.¹

LAMP-1 STUDY RESULT

AIM 0.01%, 0.025%, and 0.05% atropine eye drops reduce spherical equivalent (SE) progression and axial elongation (AL).¹




Figure 1. Change in Spherical Equivalent (SE) in Treatment Groups Across Time. m = month; D = diopter.¹





Figure 2. Change in Axial Length (AL) in Treatment Groups Across Time. m = month.¹

Low-concentration atropine eye drop helps to prevent onset of myopia among 4 – 9 years old children²

LAMP-2 STUDY RESULT

Significant reduction in the incidence of myopia and fast myopia shift with application of AIM atropine eye drops.²



Efficacy	Placebo Group	0.01% Atropine Group	0.05% Atropine Group
2-year cumulative incidence rates of myopia	53.0%	45.9%	28.4%
Fast myopia shift at 2 years	53.9%	45.1%	25.0%




Figure 3. Time to Myopia Onset by Treatment Group²




Figure 4. Spherical Equivalent Myopia Shift²